文献速递骨质疏松与代谢性骨病

口服糖皮质激素与重症肌无力患者主要骨质疏松性骨折风险

The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis.
PubMed 文献 · Osteoporos Int · 2021-10-03

该研究基于丹麦全国1995–2011年病例对照数据,纳入376858例主要骨质疏松性骨折(MOF)患者及等量对照,评估重症肌无力(MG)患者使用口服糖皮质激素(GC)的MOF风险。结果显示当前使用GC者校正OR为1.26(95%CI 0.68–2.33),最高累积剂量(≥7g)OR为2.00(95%CI 0.90–4.44),合并分析亦无显著关联。结论认为GC使用未增加MOF风险,但仍建议按指南预防骨质疏松。

要点

  • MG患者当前口服GC与MOF风险无显著关联(ORadj. 1.26,95%CI 0.68–2.33)。
  • 最高累积剂量(≥7g)未显示MOF风险增加(ORadj. 2.00,95%CI 0.90–4.44)。
  • 合并分析同样未发现口服GC使用与MOF风险的关联。

核心结论

  • 口服GC用于MG患者未与MOF风险增加相关,在病例对照研究和合并分析中均一致。
  • 基于临床指南的骨质疏松预防在MG患者中仍值得推荐。

研究设计与样本

  • 丹麦全国性人群病例对照研究(1995–2011年),病例为发生MOF者,对照为未发生MOF者,均≥18岁。
  • 采用多因素条件logistic回归估计MG患者使用口服GC versus 非使用者的OR,并校正合并症和合并用药。
  • 合并分析采用通用逆方差法、随机效应模型整合既往研究数据。

主要发现

  • 共识别376858例MOF病例和376858例对照。
  • MG患者当前使用口服GC compared with 未使用口服GC者,MOF的ORadj.为1.26(95%CI 0.68–2.33)。
  • MG患者使用最高累积剂量口服GC(≥7g)compared with 未使用者,MOF的ORadj.为2.00(95%CI 0.90–4.44)。
  • 合并分析同样显示口服GC使用与MOF风险无关联。

关键数值与推荐

  • 当前口服GC使用 versus 非使用:ORadj. 1.26(95%CI 0.68–2.33)。
  • 最高累积剂量口服GC(≥7g) versus 非使用:ORadj. 2.00(95%CI 0.90–4.44)。

临床怎么用

  • 对于MG患者,口服GC治疗时MOF风险在本研究中未显著升高,但仍应依据临床指南进行骨质疏松预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Oral glucocorticoids may increase major osteoporotic fracture risk (MOF) in myasthenia gravis patients. To assess this risk, we performed a case-control study including all Danish patients with a MOF between 1995 and 2011. We also pooled our data with data from another study. We found no increased risk. Osteoporosis prevention remains advisable. PURPOSE/INTRODUCTION: The prolonged use of high doses of oral glucocorticoids (GCs), a common treatment in patients with myasthenia gravis (MG), may increase major osteoporotic fracture (MOF) risk. Previous epidemiological studies did not exclusively focus on patients with MG or had relatively few GC-exposed MG patients. Aims were to evaluate the risk of MOF in MG patients using oral GCs in a large study population and to perform a pooled analysis with data from previous work. METHODS: A population-based case-control study (1995-2011) was conducted using the Danish National Health Service. Cases had sustained a MOF, and controls had not. All were aged ≥ 18 years. Multivariate conditional logistic regression estimated odds ratios (ORs) among MG patients using oral GCs versus non-users. Adjustments were made for comorbidities and comedications. In the pooled analysis, results were pooled by the use of generic inverse variance methods, assuming a random-effects model. RESULTS: We identified 376,858 cases and 376,858 controls. MOF risk was not elevated in MG patients currently using oral GCs compared to MG patients not on oral GCs (ORadj.: 1.26 (95% CI 0.68-2.33)). The use of the highest cumulative dose of oral GCs (≥ 7 g) did not show an increased risk of MOF among MG patients (ORadj.: 2.00 (95% CI 0.90-4.44)). Our pooled analysis also showed no association between oral GC use and MOF risk. CONCLUSION: This study showed that oral GC use in patients with MG was not associated with increased risk of MOF in our case-control study and pooled analysis. Osteoporosis prevention in MG patients based on clinical guidelines remains advisable.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Safipour Z, van der Zanden R, van den Bergh J, et al. The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis. Osteoporos Int. 2021. PMID: 34601629. doi:10.1007/s00198-021-06101-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。